Jaguar Health Converts Series R Preferred Shares Into Common Stock

Jaguar Health completed the conversion of its Series R preferred stock into 13,345,986 common shares. Each Series R share converted into five common shares on November 2, 2026. Eligible warrant holders may receive up to 69,823 additional common shares.

Original reporting
Published Nov 3, 2026, 7:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 7:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jaguar Health Converts Series R Preferred Shares Into Common Stock — source image
Decision brief

The 30-second read

$JAGXBearishLow
01

Why it matters

The dilution increases share count, likely exerting modest downward pressure on the stock price.

02

Market read

A primary corporate‑action disclosure with limited trading relevance beyond the ticker itself.

03

What to watch

Potential future financing needs or strategic moves that may follow the conversion are not disclosed.

Relevance 5/10Novelty 6/10Timing: effective Nov 2 2026, reported Nov 3 2026

Background

Jaguar Health announced the conversion of its Series R preferred stock into common shares, a routine corporate action disclosed via an 8‑K filing.

Company-level read

Ticker impact

$JAGXBearishHigh confidence
Context

Jaguar Health filed an 8‑K reporting the automatic conversion of each Series R preferred share into five common shares, increasing common shares to 13,345,986.

Expected impact

likely modest price decline as market prices in the dilution from the conversion

Evidence & confidence

The filing is the first public disclosure of the conversion; dilution is a known driver of short‑term price pressure.

Market effects

Minimal impact on the broader biotech/pharma sector; the event is company‑specific.

Limited to U.S. investors holding JAGX; no broader regional effect.

Low; the conversion does not affect global markets.

Counterpoint

If the conversion unlocks liquidity for warrant holders, it could support a short‑term rally.

Key entities

  • Jaguar Health, Inc.

    Biopharma company completing a preferred‑to‑common conversion.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.